Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Autoimmune pulmonary alveolar proteinosis
Economic burden and healthcare resource utilization
2 evidence topics · 2 sources
United States claims analysis: PAP and matched-control cohorts
| Measure | PAP cohort | Control cohort |
|---|---|---|
| Participants | “2312” | “9247” |
| Average charges during follow-up, mean ± standard deviation | “$71,672.64 ± $226,117.54” | “$14,655.91 ± $74,791.03” |